中国EIP Patent 101 CornerInventionsprosecution
2021年8月13日

What is the difference between an Invention Patent and a Utility Model Patent?

There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate to shapes or structures of a product, and have a term of 10 years from the date of filing. Utility model applications are subject to preliminary examination to check for compliance with formal requirements, novelty, unity of invention and patentable subject matter. Invention patent applications are subject to search and examination similar to those conducted in other major patent offices around the world and take approximately 3 to 5 years to complete prosecution.

Novelty

Novelty requirements in China are the same for both utility model and invention patents. In particular, novelty means that, before the date of filing, no identical invention or utility model has been publicly disclosed in publications or has been publicly used or made known to the public anywhere in the world. Furthermore, there should be no other earlier-filed applications with the Chinese Patent Office, which describe the identical invention or utility model even if the publication date thereof is after the date of filing of the case of concern.

Inventive Step

The requirement for inventive step in utility model patents in China is lower than that of an invention patent. Article 22.3 of the PRC Patent Law defines inventiveness for an invention patent as prominent substantive features that represent “notable progress” as compared to technology existing before the date of filing. For utility model patents, only substantive features that represent “progress” are required for inventive step.

Advantages of UM

The advantage of filing a Chinese utility model patent is that the patent right may be obtained within a few months from filing date thereof. For products that have a relatively short product life or have a relatively low technological hurdle (e.g., where competitors may easily reverse engineer and/or copy the technology within a short period of time) a Chinese utility model patent would be ideal. In addition, legal action may be initiated immediately upon grant of the utility model patent. Before taking legal action, however, it should also be noted that an evaluation report of patentability will be required by the court, which serves as prima facie evidence for validity.

Advantages of Invention Patents

On the other hand, Chinese invention patents provide a longer term of protection and are very useful for products that require a longer period of development or that will be commercially valuable for a very longer time. This is particularly true for high technology inventions, such as pharmaceutical and biotech inventions that typically require a lengthy research and development period for the product to be finally registered and put on the market. However, as aforementioned, it will take a comparatively longer time to obtain a granted Chinese invention patent than a utility model patent, and no legal action may be taken during the pendency period. In addition, an invention patent costs more to complete prosecution than that of a utility model patent.

Same Day Applications

One strategy is to file a UM and a Chinese invention application on the same day (same day application). If an applicant chooses this strategy, typically the UM will grant first, giving the patentee certain patent rights to enforce, license, etc. Once the corresponding “sister” invention patent application is allowed, the patentee can choose to have the invention patent grant by giving up rights to the UM. This dual strategy is quite useful for those inventions with limited inventiveness, allowing applicants to obtain at least some sort of patent rights early, but also have the opportunity to prosecute an invention application without any risks of dealing with double patenting rejections and the like. Essentially, patent applicants in China can “have their cake” (the UM) “and eat it too” (the invention patent). Do note that a PCT national phase entry application must choose between a UM and an invention application, and cannot singlehandedly take advantage of the dual strategy outlined above.

Summary: Invention vs. UM Patents

The following table summarises the differences between invention patents and utility model patents.

 

Invention Patent

Utility Model Patent

Overall Cost

Higher - Filing cost would be similar to that of utility model, but, but there will be an extra cost for requesting substantive examination. Further costs for patent prosecution such as filing response to office actions will also be required.

Lower - Generally speaking, post-filing costs for utility model are much less than those of an invention application.

Subject Matter

Method, product, composition of matter

Shapes or structures of a product only

Examination

Formality & Substantive Examinations (novelty, inventiveness, sufficient disclosure, unity, etc.)

Preliminary Examination

Novelty Requirement

Yes

Yes

Inventiveness Requirement

Higher (prominent substantive features and notable progress)

Lower (substantive features and progress)

Time to Grant

Approximately 3-5 years

from filing date

Approximately 12 months from filing date

Terms of

Protection

20 years from filing date

10 years from filing date

Assumption of Validity during Patent Litigation

Yes

Yes only if an evaluation report of patentability is procured

 

Availability of

Priority Claim

Paris Convention

PCT National Phase Entry (This is typically the application type unless utility model is specified.)1

Paris Convention

PCT National Phase Entry (Only if specified as utility model during national phase entry.) 1

1 For each PCT application entering national phase in China, only one form of patent application can be filed. In other words, the PCT applicant can only choose either an invention patent application or a utility model application but cannot file both types of applications for the same PCT application. Hence if both types of protection are desired, one type or both types has/have to be filed via Paris Convention.

About the Authors

Dr. Jacqueline Lui is Founder and President of Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

2020 China Top 10 IP Cases: Winners’ Sun is truly a Winner: A Simple Selfie-Stick Utility Model Patent Crushes Infringers in China

2021年8月2日
Each year The Intellectual Property Tribunal of the Supreme People’s Court releases a list of top 10 technical intellectual property rights court case decisions. The 2020 list came out a few months ago, and we have been highlighting some of these cases. Today, we will cover a utility model patent infringement case. As one of […]

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

我们的过去活动

Top crossarrow-right